OncRef

Clinical Trial: NCT04233346

The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Otsuka Beijing Research Institute
Information Provided By:Otsuka Beijing Research Institute
Last Update Posted:2026-10-16

Study Overview

Brief Summary

This protocol will allow ponatinib with refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia

Official Title

A Phase II Multi-center, Randomized, Open-label Study of Ponatinib in Chinese Patients With Chronic Myeloid Leukemia Who Have Failed Prior TKIs or With T315I Mutation, or Ph+ALL Who Have Failed Prior TKIs or With T315I Mutation

Conditions

Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia

Intervention / Treatment

  • Drug: Ponatinib 30mg OD
  • Drug: Ponatinib 45mg OD

Other Study ID Numbers

  • 297-403-00003

Start Date (Actual)

2020-07-09

Primary Completion Date (Actual)

2022-07-22

Study Completion Date (Actual)

2026-09-08

Enrollment (Actual)

93

Study Type

Interventional

Phase

Phase 2